

# BerisÅ,av V ZlokoviÄ

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5651465/publications.pdf>

Version: 2024-02-01

274  
papers

51,102  
citations

2215

99  
h-index

1568

217  
g-index

290  
all docs

290  
docs citations

290  
times ranked

37103  
citing authors

#	ARTICLE	IF	CITATIONS
1	The small HDL particle hypothesis of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2023, 19, 391-404.	0.8	18
2	Protection of ischemic white matter and oligodendrocytes in mice by 3K3A-activated protein C. <i>Journal of Experimental Medicine</i> , 2022, 219, .	8.5	12
3	A single-cell atlas of the normal and malformed human brain vasculature. <i>Science</i> , 2022, 375, eabi7377.	12.6	129
4	Brain barriers and their potential role in migraine pathophysiology. <i>Journal of Headache and Pain</i> , 2022, 23, 16.	6.0	17
5	Bloodâ€“brain barrier link to human cognitive impairment and Alzheimerâ€™s disease. , 2022, 1, 108-115.		45
6	3K3A-Activated Protein C Protects the Blood-Brain Barrier and Neurons From Accelerated Ischemic Injury Caused by Pericyte Deficiency in Mice. <i>Frontiers in Neuroscience</i> , 2022, 16, 841916.	2.8	8
7	Prenatal disruption of bloodâ€“brain barrier formation via cyclooxygenase activation leads to lifelong brain inflammation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, e2113310119.	7.1	15
8	Imaging subtle leaks in the bloodâ€“brain barrier in the aging human brain: potential pitfalls, challenges, and possible solutions. <i>GeroScience</i> , 2022, 44, 1339-1351.	4.6	17
9	How the brain regulates its own immune system. <i>Nature Neuroscience</i> , 2022, 25, 532-534.	14.8	7
10	Characterization of perivascular space pathology in a rat model of cerebral small vessel disease by <i>in vivo</i> magnetic resonance imaging. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2022, 42, 1813-1826.	4.3	8
11	A Review of Translational Magnetic Resonance Imaging in Human and Rodent Experimental Models of Small Vessel Disease. <i>Translational Stroke Research</i> , 2021, 12, 15-30.	4.2	18
12	Cranial Suture Regeneration Mitigates Skull and Neurocognitive Defects in Craniosynostosis. <i>Cell</i> , 2021, 184, 243-256.e18.	28.9	88
13	Endothelial LRP1 protects against neurodegeneration by blocking cyclophilin A. <i>Journal of Experimental Medicine</i> , 2021, 218, .	8.5	59
14	Evidence that bloodâ€“CSF barrier transport, but not inflammatory biomarkers, change in migraine, while CSF sVCAM1 associates with migraine frequency and CSF fibrinogen. <i>Headache</i> , 2021, 61, 536-545.	3.9	13
15	Investigating the bloodâ€“spinal cord barrier in preclinical models: a systematic review of <i>in vivo</i> imaging techniques. <i>Spinal Cord</i> , 2021, 59, 596-612.	1.9	5
16	Stroke Treatment With PAR-1 Agents to Decrease Hemorrhagic Transformation. <i>Frontiers in Neurology</i> , 2021, 12, 593582.	2.4	11
17	On the intersection between systemic infection, brain vascular dysfunction and dementia. <i>Brain</i> , 2021, 144, 1629-1631.	7.6	0
18	Early neuroinflammation is associated with lower amyloid and tau levels in cognitively normal older adults. <i>Brain, Behavior, and Immunity</i> , 2021, 94, 299-307.	4.1	19

#	ARTICLE	IF	CITATIONS
19	APOE4 accelerates advanced-stage vascular and neurodegenerative disorder in old Alzheimerâ€™s mice via cyclophilin A independently of amyloid-Î². <i>Nature Aging</i> , 2021, 1, 506-520.	11.6	77
20	Acetylated tau: A missing link between head injury and dementia. <i>Med</i> , 2021, 2, 637-639.	4.4	1
21	Reply to: Rethink the classical view of cerebrospinal fluid production. <i>Nature Reviews Neurology</i> , 2021, 17, 590-591.	10.1	1
22	Editorial for â€œ<sc>MRIâ€Based</sc> Investigation of Association Between Cerebrovascular Structural Alteration and White Matter Hyperintensity Induced by High Blood Pressureâ€™. <i>Journal of Magnetic Resonance Imaging</i> , 2021, 54, 1527-1528.	3.4	0
23	Air Pollution Particulate Matter Exposure and Chronic Cerebral Hypoperfusion and Measures of White Matter Injury in a Murine Model. <i>Environmental Health Perspectives</i> , 2021, 129, 87006.	6.0	22
24	Microglia have a grip on brain microvasculature. <i>Nature Communications</i> , 2021, 12, 5290.	12.8	20
25	Air Pollution Particulate Matter Amplifies White Matter Vascular Pathology and Demyelination Caused by Hypoperfusion. <i>Frontiers in Immunology</i> , 2021, 12, 785519.	4.8	14
26	The relationship between bloodâ€brain barrier permeability and cerebral blood flow in cognitive impairment. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
27	Urine dicarboxylic acids are metabolic biomarkers of early Alzheimerâ€™s disease. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
28	Can prehospital â€œplasma supplementâ€™ neutralize the systemic storm in severe trauma?. <i>Cell Reports Medicine</i> , 2021, 2, 100481.	6.5	1
29	Functional connectivity among brain regions affected in Alzheimer's disease is associated with CSF TNF-Î± in APOE4 carriers. <i>Neurobiology of Aging</i> , 2020, 86, 112-122.	3.1	22
30	Every-other-day feeding exacerbates inflammation and neuronal deficits in 5XFAD mouse model of Alzheimer's disease. <i>Neurobiology of Disease</i> , 2020, 136, 104745.	4.4	21
31	Vascular contributions to cognitive impairment and dementia (VCID): A report from the 2018 National Heart, Lung, and Blood Institute and National Institute of Neurological Disorders and Stroke Workshop. <i>Alzheimer's and Dementia</i> , 2020, 16, 1714-1733.	0.8	108
32	Endothelial Tip Cell Finds Its Way with Piezo1. <i>Neuron</i> , 2020, 108, 5-7.	8.1	3
33	Associations between Vascular Function and Tau PET Are Associated with Global Cognition and Amyloid. <i>Journal of Neuroscience</i> , 2020, 40, 8573-8586.	3.6	60
34	Brain delivery of supplemental docosahexaenoic acid (DHA): A randomized placebo-controlled clinical trial. <i>EBioMedicine</i> , 2020, 59, 102883.	6.1	70
35	Clearance of interstitial fluid (ISF) and CSF (CLIC) groupâ€™ part of Vascular Professional Interest Area (PIA). <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12053.	2.4	53
36	Therapeutic TVs for Crossing Barriers in the Brain. <i>Cell</i> , 2020, 182, 267-269.	28.9	13

#	ARTICLE	IF	CITATIONS
37	Comparison Between Blood-Brain Barrier Water Exchange Rate and Permeability to Gadolinium-Based Contrast Agent in an Elderly Cohort. <i>Frontiers in Neuroscience</i> , 2020, 14, 571480.	2.8	30
38	Microglial activation: A process potentially related to Alzheimer's disease and late-life major depression. <i>Alzheimer's and Dementia</i> , 2020, 16, e041950.	0.8	0
39	Relationships between cerebrovascular health and tau PET uptake are associated with global cognition. <i>Alzheimer's and Dementia</i> , 2020, 16, e045326.	0.8	0
40	Channelrhodopsin Excitation Contracts Brain Pericytes and Reduces Blood Flow in the Aging Mouse Brain in vivo. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 108.	3.4	56
41	Retinal nerve fiber layer thickness predicts CSF amyloid/tau before cognitive decline. <i>PLoS ONE</i> , 2020, 15, e0232785.	2.5	31
42	Acute Ablation of Cortical Pericytes Leads to Rapid Neurovascular Uncoupling. <i>Frontiers in Cellular Neuroscience</i> , 2020, 14, 27.	3.7	50
43	3K3A-Activated Protein C Variant Does Not Interfere With the Plasma Clot Lysis Activity of Tenecteplase. <i>Stroke</i> , 2020, 51, 2236-2239.	2.0	1
44	<i>APOE4</i> Accelerates Development of Dementia After Stroke. <i>Stroke</i> , 2020, 51, 699-700.	2.0	16
45	Perivascular spaces in the brain: anatomy, physiology and pathology. <i>Nature Reviews Neurology</i> , 2020, 16, 137-153.	10.1	405
46	APOE4 leads to blood-brain barrier dysfunction predicting cognitive decline. <i>Nature</i> , 2020, 581, 71-76.	27.8	705
47	A novel sensitive assay for detection of a biomarker of pericyte injury in cerebrospinal fluid. <i>Alzheimer's and Dementia</i> , 2020, 16, 821-830.	0.8	43
48	Building vascular roadmaps: A novel toolset for visualizing and annotating whole mouse brain vasculature. <i>Lab Animal</i> , 2020, 49, 175-176.	0.4	1
49	Retinal nerve fiber layer thickness predicts CSF amyloid/tau before cognitive decline. , 2020, 15, e0232785.		0
50	Retinal nerve fiber layer thickness predicts CSF amyloid/tau before cognitive decline. , 2020, 15, e0232785.		0
51	Retinal nerve fiber layer thickness predicts CSF amyloid/tau before cognitive decline. , 2020, 15, e0232785.		0
52	Retinal nerve fiber layer thickness predicts CSF amyloid/tau before cognitive decline. , 2020, 15, e0232785.		0
53	Preventing dementia by preventing stroke: The Berlin Manifesto. <i>Alzheimer's and Dementia</i> , 2019, 15, 961-984.	0.8	200
54	Mitigating Antagonism between Transcription and Proliferation Allows Near-Deterministic Cellular Reprogramming. <i>Cell Stem Cell</i> , 2019, 25, 486-500.e9.	11.1	34

#	ARTICLE	IF	CITATIONS
55	Special topic section: linkages among cerebrovascular, cardiovascular, and cognitive disorders: Preventing dementia by preventing stroke: The Berlin Manifesto. <i>International Journal of Stroke</i> , 2019, , 174749301987191.	5.9	13
56	Pericyte constriction underlies capillary derecruitment during hyperemia in the setting of arterial stenosis. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2019, 317, H255-H263.	3.2	18
57	Pericyte loss leads to circulatory failure and pleiotrophin depletion causing neuron loss. <i>Nature Neuroscience</i> , 2019, 22, 1089-1098.	14.8	246
58	Short-term fish oil supplementation applied in presymptomatic stage of Alzheimer's disease enhances microglial/macrophage barrier and prevents neuritic dystrophy in parietal cortex of 5xFAD mouse model. <i>PLoS ONE</i> , 2019, 14, e0216726.	2.5	16
59	TRIM9-Mediated Resolution of Neuroinflammation Confers Neuroprotection upon Ischemic Stroke in Mice. <i>Cell Reports</i> , 2019, 27, 549-560.e6.	6.4	43
60	O3â€01â€01: INTERACTION BETWEEN OBESITY, BRAIN HDL, AND APOE4 GENOTYPE IN CEREBRAL AMYLOIDOSIS. <i>Alzheimer's and Dementia</i> , 2019, 15, P875.	0.8	0
61	Undetectable gadolinium brain retention in individuals with an ageâ€dependent bloodâ€brain barrier breakdown in the hippocampus and mild cognitive impairment. <i>Alzheimer's and Dementia</i> , 2019, 15, 1568-1575.	0.8	22
62	P4â€527: PERICYTE CONTRACTILITY BY OPTOGENETICS REGULATES CAPILLARY DIAMETER AND BLOOD FLOW. <i>Alzheimer's and Dementia</i> , 2019, 15, P1516.	0.8	0
63	Final Results of the RHAPSODY Trial: A Multiâ€Center, Phase 2 Trial Using a Continual Reassessment Method to Determine the Safety and Tolerability of 3K3Aâ€APC, A Recombinant Variant of Human Activated Protein C, in Combination with Tissue Plasminogen Activator, Mechanical Thrombectomy or both in Moderate to Severe Acute Ischemic Stroke. <i>Annals of Neurology</i> , 2019, 85, 125-136.	5.3	113
64	Prion Protein Antagonists Rescue Alzheimerâ€™s Amyloid-Î²-Related Cognitive Deficits. <i>Trends in Molecular Medicine</i> , 2019, 25, 74-76.	6.7	5
65	Vascular dysfunctionâ€”The disregarded partner of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2019, 15, 158-167.	0.8	454
66	Bloodâ€brain barrier breakdown is an early biomarker of human cognitive dysfunction. <i>Nature Medicine</i> , 2019, 25, 270-276.	30.7	987
67	3K3A-activated protein C blocks amyloidogenic BACE1 pathway and improves functional outcome in mice. <i>Journal of Experimental Medicine</i> , 2019, 216, 279-293.	8.5	55
68	Blood-Brain Barrier: From Physiology to Disease and Back. <i>Physiological Reviews</i> , 2019, 99, 21-78.	28.8	1,232
69	Experimental chronic cerebral hypoperfusion results in decreased pericyte coverage and increased bloodâ€brain barrier permeability in the corpus callosum. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2019, 39, 240-250.	4.3	60
70	Identification and therapeutic rescue of autophagosome and glutamate receptor defects in C9ORF72 and sporadic ALS neurons. <i>JCI Insight</i> , 2019, 4, .	5.0	37
71	Neurovascular Unit: Basic and Clinical Imaging with Emphasis on Advantages of Ferumoxytol. <i>Neurosurgery</i> , 2018, 82, 770-780.	1.1	35
72	Permeability imaging as a predictor of delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2018, 38, 973-979.	4.3	24

#	ARTICLE	IF	CITATIONS
73	Haploinsufficiency leads to neurodegeneration in C9ORF72 ALS/FTD human induced motor neurons. <i>Nature Medicine</i> , 2018, 24, 313-325.	30.7	445
74	Bloodâ€“brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders. <i>Nature Reviews Neurology</i> , 2018, 14, 133-150.	10.1	1,731
75	PAR1 biased signaling is required for activated protein C in vivo benefits in sepsis and stroke. <i>Blood</i> , 2018, 131, 1163-1171.	1.4	81
76	Understanding the role of the perivascular space in cerebral small vessel disease. <i>Cardiovascular Research</i> , 2018, 114, 1462-1473.	3.8	211
77	Can adjunctive therapies augment the efficacy of endovascular thrombolysis? A potential role for activated protein C. <i>Neuropharmacology</i> , 2018, 134, 293-301.	4.1	15
78	2313 Characterization of the host pericyte role in glioblastoma angiogenesis. <i>Journal of Clinical and Translational Science</i> , 2018, 2, 1-1.	0.6	0
79	F1â€“03â€“04: ALZHEIMER'S DISEASE: A MATTER OF BLOODâ€“BRAIN BARRIER DYSFUNCTION?. <i>Alzheimer's and Dementia</i> , 2018, 14, P205.	0.8	0
80	The role of brain vasculature in neurodegenerative disorders. <i>Nature Neuroscience</i> , 2018, 21, 1318-1331.	14.8	612
81	Blood-brain barrier-associated pericytes internalize and clear aggregated amyloid-Î² <sup>42</sup> by LRP1-dependent apolipoprotein E isoform-specific mechanism. <i>Molecular Neurodegeneration</i> , 2018, 13, 57.	10.8	164
82	In vivo imaging and analysis of cerebrovascular hemodynamic responses and tissue oxygenation in the mouse brain. <i>Nature Protocols</i> , 2018, 13, 1377-1402.	12.0	45
83	A lymphatic waste-disposal system implicated in Alzheimerâ€™s disease. <i>Nature</i> , 2018, 560, 172-174.	27.8	23
84	Activated protein C, protease activated receptor 1, and neuroprotection. <i>Blood</i> , 2018, 132, 159-169.	1.4	94
85	Altered Permeability Of The Blood-CSF Barrier In Chronic Migraine. <i>FASEB Journal</i> , 2018, 32, 922.6-922.6.	0.5	0
86	Pericyte degeneration leads to neurovascular uncoupling and limits oxygen supply to brain. <i>Nature Neuroscience</i> , 2017, 20, 406-416.	14.8	383
87	Cerebral blood flow regulation and neurovascular dysfunction in Alzheimer disease. <i>Nature Reviews Neuroscience</i> , 2017, 18, 419-434.	10.2	842
88	Remote control of BBB: A tale of exosomes and microRNA. <i>Cell Research</i> , 2017, 27, 849-850.	12.0	54
89	Alzheimerâ€™s disease: A matter of bloodâ€“brain barrier dysfunction?. <i>Journal of Experimental Medicine</i> , 2017, 214, 3151-3169.	8.5	467
90	Role of clusterin in the brain vascular clearance of amyloid-Î² <sup>42</sup> . <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 8681-8682.	7.1	79

#	ARTICLE	IF	CITATIONS
91	NIH workshop report on the trans-agency bloodâ€“brain interface workshop 2016: exploring key challenges and opportunities associated with the blood, brain and their interface. <i>Fluids and Barriers of the CNS</i> , 2017, 14, 12.	5.0	16
92	Regional early and progressive loss of brain pericytes but not vascular smooth muscle cells in adult mice with disrupted platelet-derived growth factor receptor- $\beta^2$ signaling. <i>PLoS ONE</i> , 2017, 12, e0176225.	2.5	85
93	Neurovascular and Immuno-Imaging: From Mechanisms to Therapies. Proceedings of the Inaugural Symposium. <i>Frontiers in Neuroscience</i> , 2016, 10, 46.	2.8	3
94	FTS3â€“ $\beta$ : Interactions of Vascular and Alzheimer Disease. <i>Alzheimer's and Dementia</i> , 2016, 12, P278.	0.8	0
95	Pericytes of the neurovascular unit: key functions and signaling pathways. <i>Nature Neuroscience</i> , 2016, 19, 771-783.	14.8	766
96	Activated protein C promotes neuroprotection: mechanisms and translation to the clinic. <i>Thrombosis Research</i> , 2016, 141, S62-S64.	1.7	33
97	Brain imaging of neurovascular dysfunction in Alzheimerâ€™s disease. <i>Acta Neuropathologica</i> , 2016, 131, 687-707.	7.7	160
98	Zika Virus NS4A and NS4B Proteins Deregulate Akt-mTOR Signaling in Human Fetal Neural Stem Cells to Inhibit Neurogenesis and Induce Autophagy. <i>Cell Stem Cell</i> , 2016, 19, 663-671.	11.1	437
99	3K3Aâ€“activated protein C stimulates postischemic neuronal repair by human neural stem cells in mice. <i>Nature Medicine</i> , 2016, 22, 1050-1055.	30.7	88
100	2016 Scientific Sessions Sol Sherry Distinguished Lecturer in Thrombosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016, 36, 2143-2151.	2.4	32
101	Optimal acquisition and modeling parameters for accurate assessment of low $K_{trans}$ blood-brain barrier permeability using dynamic contrast-enhanced MRI. <i>Magnetic Resonance in Medicine</i> , 2016, 75, 1967-1977.	3.0	87
102	Neurovascular dysfunction and neurodegeneration in dementia and Alzheimer's disease. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2016, 1862, 887-900.	3.8	405
103	Blood-Brain Barrier Permeability and Gadolinium. <i>JAMA Neurology</i> , 2016, 73, 13.	9.0	77
104	Consensus statement for diagnosis of subcortical small vessel disease. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2016, 36, 6-25.	4.3	173
105	Accelerated pericyte degeneration and bloodâ€“brain barrier breakdown in apolipoprotein E4 carriers with Alzheimerâ€™s disease. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2016, 36, 216-227.	4.3	464
106	Novel R41Q- and R46Q-PAR1-Modified Mice Enable Proof-of-Concept Studies for In Vivo Protective Mechanisms of Action for Activated Protein C (APC) in Sepsis and Stroke. <i>Blood</i> , 2016, 128, 13-13.	1.4	1
107	Activated protein C: biased for translation. <i>Blood</i> , 2015, 125, 2898-2907.	1.4	212
108	Impaired vascular-mediated clearance of brain amyloid beta in Alzheimerâ€™s disease: the role, regulation and restoration of LRP1. <i>Frontiers in Aging Neuroscience</i> , 2015, 7, 136.	3.4	160

#	ARTICLE	IF	CITATIONS
109	Combined neurothrombectomy or thrombolysis with adjunctive delivery of 3K3A-activated protein C in acute ischemic stroke. <i>Frontiers in Cellular Neuroscience</i> , 2015, 9, 344.	3.7	20
110	Central role for PICALM in amyloid- $\beta^2$ blood-brain barrier transcytosis and clearance. <i>Nature Neuroscience</i> , 2015, 18, 978-987.	14.8	334
111	ROCKETSHIP: a flexible and modular software tool for the planning, processing and analysis of dynamic MRI studies. <i>BMC Medical Imaging</i> , 2015, 15, 19.	2.7	63
112	7T multi-shell hybrid diffusion imaging (HYDI) for mapping brain connectivity in mice. <i>Proceedings of SPIE</i> , 2015, 9413, .	0.8	9
113	S1-01-02: Blood-brain barrier mechanisms of neurodegeneration in Alzheimer's disease. , 2015, 11, P114-P114.		1
114	Blood-Brain Barrier Breakdown in the Aging Human Hippocampus. <i>Neuron</i> , 2015, 85, 296-302.	8.1	1,436
115	GLUT1 reductions exacerbate Alzheimer's disease vasculo-neuronal dysfunction and degeneration. <i>Nature Neuroscience</i> , 2015, 18, 521-530.	14.8	496
116	Clearance systems in the brainâ€™implications for Alzheimer disease. <i>Nature Reviews Neurology</i> , 2015, 11, 457-470.	10.1	1,127
117	Cerebrospinal Fluid Biomarkers of Neurovascular Dysfunction in Mild Dementia and Alzheimer'S Disease. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2015, 35, 1055-1068.	4.3	92
118	Vascular Plasticity and Cognition During Normal Aging and Dementia. <i>JAMA Neurology</i> , 2015, 72, 495.	9.0	30
119	Shedding of soluble platelet-derived growth factor receptor- $\beta^2$ from human brain pericytes. <i>Neuroscience Letters</i> , 2015, 607, 97-101.	2.1	97
120	Establishment and Dysfunction of the Blood-Brain Barrier. <i>Cell</i> , 2015, 163, 1064-1078.	28.9	1,146
121	Vascular contributions to cognitive impairment and dementia including Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2015, 11, 710-717.	0.8	461
122	Bloodâ€™spinal cord barrier disruption contributes to early motor-neuron degeneration in ALS-model mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, E1035-42.	7.1	188
123	Cytoprotective-selective activated protein C therapy for ischaemic stroke. <i>Thrombosis and Haemostasis</i> , 2014, 112, 883-892.	3.4	43
124	Recommendations of the Alzheimer's Diseaseâ€™Related Dementias Conference. <i>Neurology</i> , 2014, 83, 851-860.	1.1	103
125	Negative regulation of NF- $\beta$ activity by brain-specific TRlpartite Motif protein 9. <i>Nature Communications</i> , 2014, 5, 4820.	12.8	62
126	The Pericyte: A Forgotten Cell Type with Important Implications for Alzheimer's Disease?. <i>Brain Pathology</i> , 2014, 24, 371-386.	4.1	198



#	ARTICLE	IF	CITATIONS
127	Blood-Brain Barrier: A Dual Life of MFSD2A?. <i>Neuron</i> , 2014, 82, 728-730.	8.1	45
128	P2-120: INCREASED CSF MATRIX METALLOPROTEINASE-9 (MMP-9) AND REDUCED WHITE MATTER INTEGRITY IN HEALTHY ELDERLY. , 2014, 10, P515-P515.		0
129	Phase 1 Safety, Tolerability and Pharmacokinetics of 3K3A-APC in Healthy Adult Volunteers. <i>Current Pharmaceutical Design</i> , 2014, 19, 7479-7485.	1.9	61
130	Bloodâ€“spinal cord barrier breakdown and pericyte reductions in amyotrophic lateral sclerosis. <i>Acta Neuropathologica</i> , 2013, 125, 111-120.	7.7	263
131	Cerebrovascular Effects of Apolipoprotein E. <i>JAMA Neurology</i> , 2013, 70, 440.	9.0	218
132	Activated protein C analog promotes neurogenesis and improves neurological outcome after focal ischemic stroke in mice via protease activated receptor 1. <i>Brain Research</i> , 2013, 1507, 97-104.	2.2	25
133	Neurotoxicity of the anticoagulant-selective E149A-activated protein C variant after focal ischemic stroke in mice. <i>Blood Cells, Molecules, and Diseases</i> , 2013, 51, 104-108.	1.4	9
134	An Activated Protein C Analog Stimulates Neuronal Production by Human Neural Progenitor Cells via a PAR1-PAR3-S1PR<sub>1</sub>-Akt Pathway. <i>Journal of Neuroscience</i> , 2013, 33, 6181-6190.	3.6	54
135	Relationship Between Cyclophilin A Levels and Matrix Metalloproteinase 9 Activity in Cerebrospinal Fluid of Cognitively Normal Apolipoprotein E4 Carriers and Blood-Brain Barrier Breakdown. <i>JAMA Neurology</i> , 2013, 70, 1198.	9.0	93
136	Activated Protein C Analog Protects From Ischemic Stroke and Extends the Therapeutic Window of Tissue-Type Plasminogen Activator in Aged Female Mice and Hypertensive Rats. <i>Stroke</i> , 2013, 44, 3529-3536.	2.0	56
137	A gliovascular idea for the white matter repair?. <i>Journal of Neurochemistry</i> , 2013, 125, 172-174.	3.9	2
138	A Lipoprotein Receptor Cluster IV Mutant Preferentially Binds Amyloid-Î² and Regulates Its Clearance from the Mouse Brain. <i>Journal of Biological Chemistry</i> , 2013, 288, 15154-15166.	3.4	33
139	Deficiency in Mural Vascular Cells Coincides with Bloodâ€“Brain Barrier Disruption in <scp>A</scp> Alzheimer's Disease. <i>Brain Pathology</i> , 2013, 23, 303-310.	4.1	409
140	Bloodâ€“Spinal Cord Barrier Pericyte Reductions Contribute to Increased Capillary Permeability. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2012, 32, 1841-1852.	4.3	171
141	Low-density lipoprotein receptor overexpression enhances the rate of brain-to-blood AÎ² clearance in a mouse model of Î²-amyloidosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 15502-15507.	7.1	138
142	Preclinical Safety and Pharmacokinetic Profile of 3K3A-APC, a Novel, Modified Activated Protein C for Ischemic Stroke. <i>Current Pharmaceutical Design</i> , 2012, 18, 4215-4222.	1.9	50
143	Neurovascular Defects and Faulty Amyloid-Î² Vascular Clearance in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2012, 33, S87-S100.	2.6	100
144	An Activated Protein C Analog With Reduced Anticoagulant Activity Extends the Therapeutic Window of Tissue Plasminogen Activator for Ischemic Stroke in Rodents. <i>Stroke</i> , 2012, 43, 2444-2449.	2.0	65

#	ARTICLE	IF	CITATIONS
145	Neurovascular Dysfunction and Faulty Amyloid A-Peptide Clearance in Alzheimer Disease. Cold Spring Harbor Perspectives in Medicine, 2012, 2, a011452-a011452.	6.2	207
146	Protein C anticoagulant and cytoprotective pathways. International Journal of Hematology, 2012, 95, 333-345.	1.6	110
147	Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature, 2012, 485, 512-516.	27.8	1,019
148	A multimodal RAGE-specific inhibitor reduces amyloid A-mediated brain disorder in a mouse model of Alzheimer disease. Journal of Clinical Investigation, 2012, 122, 1377-1392.	8.2	507
149	Hypertension Induces Brain A <sup>2</sup> -Amyloid Accumulation, Cognitive Impairment, and Memory Deterioration Through Activation of Receptor for Advanced Glycation End Products in Brain Vasculature. Hypertension, 2012, 60, 188-197.	2.7	199
150	Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nature Reviews Neuroscience, 2011, 12, 723-738.	10.2	2,254
151	Lack of Smad or Notch Leads to a Fatal Game of Brain Pericyte Hopscotch. Developmental Cell, 2011, 20, 279-280.	7.0	24
152	Cytoprotective protein C pathways and implications for stroke and neurological disorders. Trends in Neurosciences, 2011, 34, 198-209.	8.6	129
153	Impaired Lipoprotein Receptor-Mediated Peripheral Binding of Plasma Amyloid-A <sup>2</sup> is an Early Biomarker for Mild Cognitive Impairment Preceding Alzheimer's Disease. Journal of Alzheimer's Disease, 2011, 24, 25-34.	2.6	63
154	Methamphetamine causes sustained depression in cerebral blood flow. Brain Research, 2011, 1373, 91-100.	2.2	50
155	Central nervous system pericytes in health and disease. Nature Neuroscience, 2011, 14, 1398-1405.	14.8	806
156	From the liver to the blood-brain barrier: An interconnected system regulating brain amyloid-A <sup>2</sup> levels. Journal of Neuroscience Research, 2011, 89, 967-968.	2.9	24
157	Microhemorrhages: Undetectable but clinically meaningful the question persists. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2011, 12, 231-232.	2.1	2
158	Activated Protein C is Neuroprotective and Mediates New Blood Vessel Formation and Neurogenesis After Controlled Cortical Impact. Neurosurgery, 2010, 66, 165-172.	1.1	55
159	Protein S controls hypoxic/ischemic blood-brain barrier disruption through the TAM receptor Tyro3 and sphingosine 1-phosphate receptor. Blood, 2010, 115, 4963-4972.	1.4	95
160	Impaired spine formation and learning in GPCR kinase 2 interacting protein-1 (GIT1) knockout mice. Brain Research, 2010, 1317, 218-226.	2.2	42
161	Activated protein C analog with reduced anticoagulant activity improves functional recovery and reduces bleeding risk following controlled cortical impact. Brain Research, 2010, 1347, 125-131.	2.2	36
162	Pericyte-specific expression of PDGF beta receptor in mouse models with normal and deficient PDGF beta receptor signaling. Molecular Neurodegeneration, 2010, 5, 32.	10.8	274

#	ARTICLE	IF	CITATIONS
163	Low-density lipoprotein receptor-related protein-1: a serial clearance homeostatic mechanism controlling Alzheimer's amyloid $\beta$ peptide elimination from the brain. <i>Journal of Neurochemistry</i> , 2010, 115, 1077-1089.	3.9	212
164	Neurodegeneration and the neurovascular unit. <i>Nature Medicine</i> , 2010, 16, 1370-1371.	30.7	174
165	Protein S Protects Neurons from Excitotoxic Injury by Activating the TAM Receptor Tyro3-Phosphatidylinositol 3-Kinase-Akt Pathway through Its Sex Hormone-Binding Globulin-Like Region. <i>Journal of Neuroscience</i> , 2010, 30, 15521-15534.	3.6	57
166	Pericytes Control Key Neurovascular Functions and Neuronal Phenotype in the Adult Brain and during Brain Aging. <i>Neuron</i> , 2010, 68, 409-427.	8.1	1,192
167	Species-specific anticoagulant and mitogenic activities of murine protein S. <i>Haematologica</i> , 2009, 94, 1721-1731.	3.5	19
168	Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer's disease. <i>Acta Neuropathologica</i> , 2009, 118, 103-113.	7.7	769
169	Endothelial Protein C Receptor-Assisted Transport of Activated Protein C across the Mouse Blood-Brain Barrier. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2009, 29, 25-33.	4.3	64
170	SRF and myocardin regulate LRP-mediated amyloid- $\beta$ clearance in brain vascular cells. <i>Nature Cell Biology</i> , 2009, 11, 143-153.	10.3	237
171	Neuroprotective activities of activated protein C mutant with reduced anticoagulant activity. <i>European Journal of Neuroscience</i> , 2009, 29, 1119-1130.	2.6	83
172	Species-dependent neuroprotection by activated protein C mutants with reduced anticoagulant activity. <i>Journal of Neurochemistry</i> , 2009, 109, 116-124.	3.9	33
173	Activated protein C therapy slows ALS-like disease in mice by transcriptionally inhibiting SOD1 in motor neurons and microglia cells. <i>Journal of Clinical Investigation</i> , 2009, 119, 3437-49.	8.2	158
174	Differential Neuroprotection and Risk for Bleeding From Activated Protein C With Varying Degrees of Anticoagulant Activity. <i>Stroke</i> , 2009, 40, 1864-1869.	2.0	52
175	New Therapeutic Targets in the Neurovascular Pathway in Alzheimer's Disease. <i>Neurotherapeutics</i> , 2008, 5, 409-414.	4.4	138
176	ALS-causing SOD1 mutants generate vascular changes prior to motor neuron degeneration. <i>Nature Neuroscience</i> , 2008, 11, 420-422.	14.8	409
177	Coupling of Angiogenesis and Neurogenesis in Cultured Endothelial Cells and Neural Progenitor Cells after Stroke. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2008, 28, 764-771.	4.3	230
178	The Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders. <i>Neuron</i> , 2008, 57, 178-201.	8.1	2,712
179	Myocardin Is Sufficient for a Smooth Muscle-Like Contractile Phenotype. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2008, 28, 1505-1510.	2.4	112
180	apoE isoform-specific disruption of amyloid $\beta$ peptide clearance from mouse brain. <i>Journal of Clinical Investigation</i> , 2008, 118, 4002-4013.	8.2	623

#	ARTICLE	IF	CITATIONS
181	Activated Protein C Promotes Neovascularization and Neurogenesis in Postischemic Brain via Protease-Activated Receptor 1. <i>Journal of Neuroscience</i> , 2008, 28, 12788-12797.	3.6	104
182	Endothelial Cell Protein C Receptor. <i>Circulation Research</i> , 2007, 100, 155-157.	4.5	601
183	Role of the Blood-Brain Barrier in the Pathogenesis of Alzheimers Disease. <i>Current Alzheimer Research</i> , 2007, 4, 191-197.	1.4	333
184	Serum response factor and myocardin mediate arterial hypercontractility and cerebral blood flow dysregulation in Alzheimer's phenotype. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 823-828.	7.1	189
185	The cytoprotective protein C pathway. <i>Blood</i> , 2007, 109, 3161-3172.	1.4	714
186	Clearance of amyloid-Î² by circulating lipoprotein receptors. <i>Nature Medicine</i> , 2007, 13, 1029-1031.	30.7	381
187	Transport Pathways for Clearance of Human Alzheimer's Amyloid Î²-Peptide and Apolipoproteins E and J in the Mouse Central Nervous System. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2007, 27, 909-918.	4.3	576
188	Two-Photon Imaging of Astrocytic Ca <sup>2+</sup> Signaling and the Microvasculature in Experimental Mice Models of Alzheimer's Disease. <i>Annals of the New York Academy of Sciences</i> , 2007, 1097, 40-50.	3.8	145
189	The promise of protein C. <i>Blood Cells, Molecules, and Diseases</i> , 2006, 36, 211-216.	1.4	45
190	Remodeling after stroke. <i>Nature Medicine</i> , 2006, 12, 390-391.	30.7	59
191	Activated protein C inhibits tissue plasminogen activatorâ€“induced brain hemorrhage. <i>Nature Medicine</i> , 2006, 12, 1278-1285.	30.7	243
192	Role of the MEOX2 homeobox gene in neurovascular dysfunction in Alzheimer disease. <i>Nature Medicine</i> , 2005, 11, 959-965.	30.7	274
193	Functional recovery after embolic stroke in rodents by activated protein C. <i>Annals of Neurology</i> , 2005, 58, 474-477.	5.3	67
194	IgG-Assisted Age-Dependent Clearance of Alzheimer's Amyloid Å Peptide by the Blood-Brain Barrier Neonatal Fc Receptor. <i>Journal of Neuroscience</i> , 2005, 25, 11495-11503.	3.6	238
195	Neurovascular mechanisms of Alzheimer's neurodegeneration. <i>Trends in Neurosciences</i> , 2005, 28, 202-208.	8.6	856
196	Neurovascular Pathways and Alzheimer Amyloid Î²-peptide. <i>Brain Pathology</i> , 2005, 15, 78-83.	4.1	95
197	P-glycoprotein deficiency at the blood-brain barrier increases amyloid-Å deposition in an Alzheimer disease mouse model. <i>Journal of Clinical Investigation</i> , 2005, 115, 3285-3290.	8.2	564
198	RAGE (Yin) Versus LRP (Yang) Balance Regulates Alzheimer Amyloid Î²-Peptide Clearance Through Transport Across the Bloodâ€“Brain Barrier. <i>Stroke</i> , 2004, 35, 2628-2631.	2.0	362

#	ARTICLE	IF	CITATIONS
199	Early-onset and Robust Cerebral Microvascular Accumulation of Amyloid Î²-Protein in Transgenic Mice Expressing Low Levels of a Vasculotropic Dutch/Iowa Mutant Form of Amyloid Î²-Protein Precursor. <i>Journal of Biological Chemistry</i> , 2004, 279, 20296-20306.	3.4	315
200	Clearing amyloid through the blood-brain barrier. <i>Journal of Neurochemistry</i> , 2004, 89, 807-811.	3.9	324
201	Advances in restorative neurosurgery: Endovascular delivery and fate determination of transplanted stem cells. <i>Seminars in Anesthesia</i> , 2004, 23, 248-257.	0.3	0
202	Method for measurement of the blood-brain barrier permeability in the perfused mouse brain: application to amyloid-Î² peptide in wild type and Alzheimer's Tg2576 mice. <i>Journal of Neuroscience Methods</i> , 2004, 138, 233-242.	2.5	57
203	Brain capillary endothelium and choroid plexus epithelium regulate transport of transferrin-bound and free iron into the rat brain. <i>Journal of Neurochemistry</i> , 2004, 88, 813-820.	3.9	94
204	LRP/Amyloid Î²-Peptide Interaction Mediates Differential Brain Efflux of AÎ² Isoforms. <i>Neuron</i> , 2004, 43, 333-344.	8.1	752
205	Presence and Functional Activity of the Aryl Hydrocarbon Receptor in Isolated Murine Cerebral Vascular Endothelial Cells and Astrocytes. <i>NeuroToxicology</i> , 2004, 25, 605-616.	3.0	68
206	Activated Protein C Prevents Neuronal Apoptosis via Protease Activated Receptors 1 and 3. <i>Neuron</i> , 2004, 41, 563-572.	8.1	243
207	Activated protein C and ischemic stroke. <i>Critical Care Medicine</i> , 2004, 32, S247-S253.	0.9	47
208	A simple method for isolation and characterization of mouse brain microvascular endothelial cells. <i>Journal of Neuroscience Methods</i> , 2003, 130, 53-63.	2.5	106
209	Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective. <i>Nature Medicine</i> , 2003, 9, 338-342.	30.7	556
210	RAGE mediates amyloid-Î² peptide transport across the blood-brain barrier and accumulation in brain. <i>Nature Medicine</i> , 2003, 9, 907-913.	30.7	1,277
211	Recombinant murine-activated protein C is neuroprotective in a murine ischemic stroke model. <i>Blood Cells, Molecules, and Diseases</i> , 2003, 30, 271-276.	1.4	71
212	Protein S Confers Neuronal Protection During Ischemic/Hypoxic Injury in Mice. <i>Circulation</i> , 2003, 107, 1791-1796.	1.6	86
213	Activated protein C alters cytosolic calcium flux in human brain endothelium via binding to endothelial protein C receptor and activation of protease activated receptor-1. <i>Blood</i> , 2003, 101, 4797-4801.	1.4	107
214	Endovascular Restorative Neurosurgery: A Novel Concept for Molecular and Cellular Therapy of the Nervous System. <i>Neurosurgery</i> , 2003, 52, 402-413.	1.1	27
215	Brain Clearance of Alzheimer's Amyloid-Î²40 in the Squirrel Monkey: A SPECT Study in a Primate Model of Cerebral Amyloid Angiopathy. <i>Journal of Drug Targeting</i> , 2002, 10, 359-368.	4.4	89
216	Activated protein C: Potential therapy for severe sepsis, thrombosis, and stroke. <i>Seminars in Hematology</i> , 2002, 39, 197-205.	3.4	85

#	ARTICLE	IF	CITATIONS
217	Vascular disorder in Alzheimer's disease: role in pathogenesis of dementia and therapeutic targets. <i>Advanced Drug Delivery Reviews</i> , 2002, 54, 1553-1559.	13.7	56
218	Circulating amyloid- $\beta$ peptide crosses the blood-brain barrier in aged monkeys and contributes to Alzheimer's disease lesions. <i>Vascular Pharmacology</i> , 2002, 38, 303-313.	2.1	127
219	Current treatments and therapeutic targets in Alzheimer's disease. <i>Advanced Drug Delivery Reviews</i> , 2002, 54, 1533-7.	13.7	2
220	Preferential Susceptibility of Brain Tumors to the Antiangiogenic Effects of an $\alpha_v$ Integrin Antagonist. <i>Neurosurgery</i> , 2001, 48, 151-157.	1.1	157
221	Anti-Inflammatory, Antithrombotic, and Neuroprotective Effects of Activated Protein C in a Murine Model of Focal Ischemic Stroke. <i>Circulation</i> , 2001, 103, 1799-1805.	1.6	202
222	Apolipoprotein J (clusterin) and Alzheimer's disease. <i>Microscopy Research and Technique</i> , 2000, 50, 305-315.	2.2	226
223	Brain Injury and Cerebrovascular Fibrin Deposition Correlate with Reduced Antithrombotic Brain Capillary Functions in a Hypertensive Stroke Model. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2000, 20, 998-1009.	4.3	20
224	Differential Regulation of Leptin Transport by the Choroid Plexus and Blood-Brain Barrier and High Affinity Transport Systems for Entry into Hypothalamus and Across the Blood-Cerebrospinal Fluid Barrier*. <i>Endocrinology</i> , 2000, 141, 1434-1441.	2.8	147
225	Clearance of Alzheimer's amyloid- $\beta$ 1-40 peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. <i>Journal of Clinical Investigation</i> , 2000, 106, 1489-1499.	8.2	1,213
226	Apolipoprotein J (clusterin) and Alzheimer's disease. <i>Microscopy Research and Technique</i> , 2000, 50, 305-315.	2.2	5
227	Differential Regulation of Leptin Transport by the Choroid Plexus and Blood-Brain Barrier and High Affinity Transport Systems for Entry into Hypothalamus and Across the Blood-Cerebrospinal Fluid Barrier. <i>Endocrinology</i> , 2000, 141, 1434-1441.	2.8	44
228	Retroviral Vector-Mediated Transfer and Expression of Human Tissue Plasminogen Activator cDNA in Bovine Brain Endothelial Cells. <i>Neurosurgery</i> , 1999, 45, 962-970.	1.1	7
229	Tissue Plasminogen Activator (tPA) Deficiency Exacerbates Cerebrovascular Fibrin Deposition and Brain Injury in a Murine Stroke Model. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1999, 19, 2801-2806.	2.4	127
230	Cereport (RMP-7) increases the permeability of human brain microvascular endothelial cell monolayers. <i>Pharmaceutical Research</i> , 1999, 16, 1360-1365.	3.5	34
231	Exogenous microglia enter the brain and migrate into ischaemic hippocampal lesions. <i>Neuroscience Letters</i> , 1999, 272, 127-130.	2.1	25
232	Corneal Transport of Circulating Glutathione in Normal and Galactosemic Guinea Pigs. <i>Cornea</i> , 1999, 18, 321.	1.7	16
233	Measurement of Thrombomodulin mRNA Expression in Brain Capillaries by Polymerase Chain Reaction. <i>Thrombosis Research</i> , 1998, 91, 191-197.	1.7	7
234	Rat Brain Capillary Thrombomodulin. <i>Thrombosis Research</i> , 1998, 92, 213-219.	1.7	6

#	ARTICLE	IF	CITATIONS
235	Circulating Antibody against Tumor Necrosis Factor $\alpha$ Protects Rat Brain from Reperfusion Injury. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1998, 18, 52-58.	4.3	179
236	Immunohistochemical Localization of Tissue Plasminogen Activator in Vascular Endothelium of Stroke-prone Regions of the Rat Brain. <i>Neurosurgery</i> , 1998, 43, 909-913.	1.1	27
237	Strategies to Circumvent Vascular Barriers of the Central Nervous System. <i>Neurosurgery</i> , 1998, 43, 877-878.	1.1	46
238	Survival and Toxicity of an Allogeneic Cytokine-secreting Fibroblast Vaccine in the Central Nervous System. <i>Neurosurgery</i> , 1998, 42, 340-340.	1.1	0
239	Cerebrovascular Accumulation and Increased Blood-Brain Barrier Permeability to Circulating Alzheimer's Amyloid $\beta$ Peptide in Aged Squirrel Monkey with Cerebral Amyloid Angiopathy. <i>Journal of Neurochemistry</i> , 1998, 70, 210-215.	3.9	128
240	Detection of Brain Tumor Invasion and Micrometastasis in Vivo by Expression of Enhanced Green Fluorescent Protein. <i>Neurosurgery</i> , 1998, 43, 1437-1442.	1.1	27
241	Cellular and Molecular Neurosurgery: Pathways from Concept to Reality-Part I: Target Disorders and Concept Approaches to Gene Therapy of the Central Nervous System. <i>Neurosurgery</i> , 1997, 40, 789-804.	1.1	97
242	Cellular and Molecular Neurosurgery: Pathways from Concept to Reality-Part II: Vector Systems and Delivery Methodologies for Gene Therapy of the Central Nervous System. <i>Neurosurgery</i> , 1997, 40, 805-813.	1.1	117
243	Neuroprotective effects of nicardipine in a rat model of ischemia and reperfusion. <i>Neurosurgical Focus</i> , 1997, 2, E4.	2.3	1
244	Attenuation of brain injury and reduction of neuron-specific enolase by nicardipine in systemic circulation following focal ischemia and reperfusion in a rat model. <i>Journal of Neurosurgery</i> , 1997, 87, 731-737.	1.6	31
245	Liver and lens glutathione and cysteine regulation in galactose-fed guinea pigs. <i>Current Eye Research</i> , 1997, 16, 365-371.	1.5	6
246	Low de novo Glutathione Synthesis from Circulating Sulfur Amino Acids in the Lens Epithelium. <i>Experimental Eye Research</i> , 1997, 64, 615-626.	2.6	10
247	Thrombomodulin Expression in Bovine Brain Capillaries. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1997, 17, 3139-3146.	2.4	36
248	Chronic Nicotine Treatment Enhances Focal Ischemic Brain Injury and Depletes Free Pool of Brain Microvascular Tissue Plasminogen Activator in Rats. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1997, 17, 136-146.	4.3	109
249	Intravenous infusion of RMP-7 increases ocular uptake of ganciclovir. <i>Pharmaceutical Research</i> , 1997, 14, 80-85.	3.5	9
250	Isoform $\alpha$ -specific Effects of Apolipoproteins E2, E3, and E4 on Cerebral Capillary Sequestration and Blood-Brain Barrier Transport of Circulating Alzheimer's Amyloid $\beta$ . <i>Journal of Neurochemistry</i> , 1997, 69, 1995-2004.	3.9	138
251	Cerebrovascular transport of Alzheimer's amyloid $\beta$ and apolipoproteins J and E: Possible anti-amyloidogenic role of the blood-brain barrier. <i>Life Sciences</i> , 1996, 59, 1483-1497.	4.3	135
252	Transport of Circulating Reduced Glutathione at the Basolateral Side of the Anterior Lens Epithelium: Physiologic Importance and Manipulations. <i>Experimental Eye Research</i> , 1996, 62, 29-38.	2.6	44

#	ARTICLE	IF	CITATIONS
253	Blood-brain barrier uptake of the 40 and 42 amino acid sequences of circulating Alzheimer's amyloid $\beta^2$ in guinea pigs. <i>Neuroscience Letters</i> , 1996, 206, 157-160.	2.1	84
254	Cellular Uptake and Transport of Methylprednisolone at the Blood-Brain Barrier. <i>Neurosurgery</i> , 1996, 38, 348-354.	1.1	24
255	Transport of dopamine at the blood-brain barrier of the guinea pig: inhibition by psychotropic drugs and nicotine. <i>Pharmaceutical Research</i> , 1996, 13, 290-295.	3.5	14
256	Evidence for the Existence of a Sodium-dependent Glutathione (GSH) Transporter. <i>Journal of Biological Chemistry</i> , 1996, 271, 9754-9758.	3.4	67
257	Brain Capillary Tissue Plasminogen Activator in a Diabetes Stroke Model. <i>Stroke</i> , 1996, 27, 712-719.	2.0	41
258	Expression of Tissue Plasminogen Activator in Cerebral Capillaries. <i>Neurosurgery</i> , 1995, 37, 955-960.	1.1	58
259	Cerebrovascular permeability to peptides: manipulations of transport systems at the blood-brain barrier. <i>Pharmaceutical Research</i> , 1995, 12, 1395-1406.	3.5	124
260	Blood-to-lens Transport of Reduced Glutathione in an In Situ Perfused Guinea-pig Eye. <i>Experimental Eye Research</i> , 1994, 59, 487-496.	2.6	19
261	A Simple Technique to Determine Glutathione (GSH) Levels and Synthesis in Ocular Tissues as GSH-bimane Adduct: Application to Normal and Galactosemic Guinea-pigs. <i>Experimental Eye Research</i> , 1993, 56, 45-50.	2.6	29
262	Transport, uptake, and metabolism of blood-borne vasopressin by the blood-brain barrier. <i>Brain Research</i> , 1992, 590, 213-218.	2.2	45
263	An in situ perfused guinea-pig eye model for blood-ocular transport studies: Application to amino acids. <i>Experimental Eye Research</i> , 1992, 54, 471-477.	2.6	12
264	In vivo approaches for studying peptide interactions at the blood " brain barrier. <i>Journal of Controlled Release</i> , 1990, 13, 185-201.	9.9	21
265	Kinetic Analysis of Leucine-Enkephalin Cellular Uptake at the Luminal Side of the Blood-Brain Barrier of an In Situ Perfused Guinea-Pig Brain. <i>Journal of Neurochemistry</i> , 1989, 53, 1333-1340.	3.9	85
266	Saturable mechanism for delta sleep-inducing peptide (DSIP) at the blood-brain barrier of the vascularly perfused guinea pig brain. <i>Peptides</i> , 1989, 10, 249-254.	2.4	32
267	Chronic amphetamine intoxication and the blood-brain barrier permeability to inert polar molecules studied in the vascularly perfused guinea pig brain. <i>Journal of the Neurological Sciences</i> , 1989, 94, 41-50.	0.6	15
268	Unidirectional uptake of enkephalins at the blood-tissue interface of the blood-cerebrospinal fluid barrier: a saturable mechanism. <i>Regulatory Peptides</i> , 1988, 20, 33-44.	1.9	27
269	Passage of delta sleep-inducing peptide (DSIP) across the blood-cerebrospinal fluid barrier. <i>Peptides</i> , 1988, 9, 533-538.	2.4	28
270	Transport of Leucine-Enkephalin Across the Blood-Brain Barrier in the Perfused Guinea Pig Brain. <i>Journal of Neurochemistry</i> , 1987, 49, 310-315.	3.9	120



#	ARTICLE	IF	CITATIONS
271	Blood-brain barrier permeability to leucine-enkephalin,d-Alanine2-d-leucine5-enkephalin and their N-terminal amino acid (tyrosine). Brain Research, 1985, 336, 125-132.	2.2	111
272	Permeability of the blood-cerebrospinal fluid and blood-brain barriers to thyrotropin-releasing hormone. Brain Research, 1985, 358, 191-199.	2.2	93
273	Blood-brain barrier permeability to dipeptides and their constituent amino acids. Brain Research, 1983, 271, 65-71.	2.2	36
274	PROTECTIVE EFFECTS OF GLUCAGON DURING THE ANAPHYLACTIC RESPONSE IN GUINEAâ€PIG ISOLATED HEART. British Journal of Pharmacology, 1982, 76, 483-489.	5.4	8